Evidence map›Paper›PMID 42518147›Full record

ReviewAnnals of surgical oncology2026

Locally Recurrent Rectal Cancer in the Molecular Era: A Scoping Review of Biomarkers of Oncologic Outcome following Salvage Surgery.

Jennifer K Vu, Evonne Younan, Sascha Karunaratne, Sarah Sutherland, Paul A Sutton, Y Nancy You, Oliver Peacock, Daniel Steffens, Michael J Solomon, Kilian G M Brown

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jennifer K VuDepartment of Colorectal Surgery, Royal Prince Alfred Hospital and Chris O'Brien Lifehouse, Sydney, Australia.
Evonne YounanDepartment of Colorectal Surgery, Royal Prince Alfred Hospital and Chris O'Brien Lifehouse, Sydney, Australia.
Sascha KarunaratneSurgical Outcomes Research Centre (SOuRCe), RPA Institute of Academic Surgery, Sydney, Australia.
Sarah SutherlandFaculty of Medicine and Health, The University of Sydney, New South Wales, Australia.
Paul A SuttonSurgical Outcomes Research Centre (SOuRCe), RPA Institute of Academic Surgery, Sydney, Australia.
Y Nancy YouDepartment of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oliver PeacockDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Daniel SteffensSurgical Outcomes Research Centre (SOuRCe), RPA Institute of Academic Surgery, Sydney, Australia.
Michael J SolomonDepartment of Colorectal Surgery, Royal Prince Alfred Hospital and Chris O'Brien Lifehouse, Sydney, Australia.
Kilian G M BrownDepartment of Colorectal Surgery, Royal Prince Alfred Hospital and Chris O'Brien Lifehouse, Sydney, Australia. kilian.brown@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadical salvage surgery offers the only chance of cure for patients with locally recurrent rectal cancer (LRRC), yet up to 50% develop disease recurrence after surgery. Identification of those at highest risk of disease recurrence may improve selection for surgery and intensification of neoadjuvant treatment. This scoping review aimed to identify molecular determinants of oncologic outcomes following surgery for LRRC. MATERIALS AND

methodsThis study was conducted in accordance with the Joanna Briggs Institute (JBI) methodology for scoping reviews. MEDLINE, Embase, CENTRAL, and Scopus databases were searched for articles published between 2005 and 2025 that reported associations between blood, tissue, or other molecular factors and postoperative oncologic outcomes (recurrence and survival) in patients undergoing treatment for LRRC.

resultsThe search identified 2799 articles, of which 17 were included. Sample size varied from 21 to 213 patients. Locoregional recurrence rates after surgery ranged from 15% to 52% (various timepoints between 3 and 5 years), while 5-year overall survival ranged from 22% to 53%. Elevated carcinoembryonic antigen (CEA) was associated with shorter overall survival in 11 studies, and poorer relapse-free survival in 1 study. Elevated serum carbohydrate antigen 19-9 (CA19-9) was associated with shorter overall survival and disease-specific survival in two studies. No studies evaluating contemporary biomarkers (mutational profile, microsatellite instability, or circulating-tumour DNA) were identified.

conclusionsEvidence evaluating molecular biomarkers in LRRC is limited and has focused on traditional serum biomarkers such as CEA and CA19-9. Contemporary colorectal cancer biomarkers including mutational profile and ctDNA are yet to be studied in this population.

Indexed as

Locally recurrent rectal cancerMolecular biomarkersOncologic outcomesSurgery

Identifiers

PMID42518147

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.